Physiomics (GB:PYC) has released an update.
Physiomics PLC has secured a new contract with Cancer Research UK to develop a pharmacokinetic-pharmacodynamic model for a novel cancer therapy, aiming to refine starting doses for upcoming human trials. This deal highlights Physiomics’ expertise in using advanced data science for drug development and strengthens its ongoing collaboration with Cancer Research UK.
For further insights into GB:PYC stock, check out TipRanks’ Stock Analysis page.
